Great Point Partners LLC cut its stake in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) by 55.9% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 674,075 shares of the company's stock after selling 855,263 shares during the period. Vistagen Therapeutics makes up approximately 0.6% of Great Point Partners LLC's holdings, making the stock its 27th largest holding. Great Point Partners LLC owned about 2.42% of Vistagen Therapeutics worth $2,029,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of VTGN. Valence8 US LP acquired a new position in Vistagen Therapeutics in the 3rd quarter worth $103,000. Blair William & Co. IL increased its position in shares of Vistagen Therapeutics by 29.2% during the second quarter. Blair William & Co. IL now owns 88,466 shares of the company's stock worth $308,000 after acquiring an additional 20,000 shares during the last quarter. Finally, American Century Companies Inc. increased its position in shares of Vistagen Therapeutics by 49.1% during the second quarter. American Century Companies Inc. now owns 30,315 shares of the company's stock worth $105,000 after acquiring an additional 9,984 shares during the last quarter. Hedge funds and other institutional investors own 78.39% of the company's stock.
Wall Street Analyst Weigh In
Separately, William Blair upgraded Vistagen Therapeutics to a "strong-buy" rating in a research note on Friday, August 30th.
Read Our Latest Research Report on VTGN
Vistagen Therapeutics Price Performance
Shares of NASDAQ:VTGN traded up $0.09 during midday trading on Wednesday, reaching $2.69. The company had a trading volume of 205,488 shares, compared to its average volume of 195,217. The stock has a market capitalization of $74.89 million, a P/E ratio of -2.10 and a beta of 0.78. The stock's fifty day moving average price is $2.96 and its 200-day moving average price is $3.38. Vistagen Therapeutics, Inc. has a one year low of $2.48 and a one year high of $5.86.
Vistagen Therapeutics Company Profile
(
Free Report)
Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.
Further Reading
Before you consider Vistagen Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vistagen Therapeutics wasn't on the list.
While Vistagen Therapeutics currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
